BTAI•benzinga•
BioXcel Therapeutics Announces 33% Enrollment In SERENITY At-Home Pivotal Phase 3 Safety Trial For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia; Topline Data Expected In 2H25
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 7, 2025 by benzinga